BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction Registry
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Heart Failure
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
Summary: The CVRx BAROSTIM THERAPY in Heart Failure with Reduced Ejection Fraction (HFrEF) Registry includes patients who have been recently implanted with the BAROSTIM NEO System for heart failure. Up to 5,000 patients will be enrolled. Patients must be enrolled within 30 days after the implant. Da...
Summary: The CVRx BAROSTIM THERAPY in Heart Failure with Reduced Ejection Fraction (HFrEF) Registry includes patients who have been recently implanted with the BAROSTIM NEO System for heart failure. Up to 5,000 patients will be enrolled. Patients must be enrolled within 30 days after the implant. Data should be obtained from standard of care measurements taken prior to implant, at implant, and every six months after device implant, up to the 36-month visit at which time each patient will be exited from the registry.
Tracking Information
- NCT #
- NCT04502316
- Collaborators
- Not Provided
- Investigators
- Study Chair: Thomas Deering Piedmont Heart Institute Study Chair: Bradley Knight Northwestern Medicine Study Chair: Larry Chinitz NYU Heart Rhythm Center Study Chair: Michael Gold Medical University of South Carolina
Get Well Soon